This spike is the signal to the pancreas for insulin release and the full signal to the brain
Fatigue (510%): Common as intake drops
Since the medication causes glucose-dependent insulin release and did not cause hypoglycemia but suppressed appetite, liraglutide and semaglutide were both approved for weight loss in patients without diabetes [33, 34]
In the retatrutide trial data above, dysesthesia jumped from 8.8% at the 9 mg dose to 20.9% at the 12 mg dosea pattern that mirrors whats been seen with another GLP-1 medication at a higher dose
Lancet Title: Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (Surmount-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial
Read our deep-dive guide: Pepcid vs Prilosec: The Difference & The GLP-1 "PPI Trap" Your Pharmacy Shopping List: Famotidine: (Generic Pepcid AC) The ideal "Goldilocks" solution for GLP-1 users